METTL16 promoted expression of branched-chain amino acid (BCAA), transaminase 1 (BCAT1) and BCAT2 through m6A-dependent manner and reprogramed BCAA metabolism in acute myeloid leukemia.22 In 2022, Ye et al.23 found that METTL16 inhibited ferroptosis to enhance the expression of GPX4, resulting in breast cancer progression. This evidence concerns the gene BCAT2 and breast carcinoma.